Search results for "From ACP Journal Club"


 
Results 21 - 30 of about 79 for "From ACP Journal Club".

Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics

The following commentary by Donald A. Smith, MD, MPH, FACP, was published in the ACP Journal Club section of the April 18 Annals of Internal Medicine. ... All articles from the May 12, 2017, ACP Diabetes Monthly Newsletter.
May 2017

Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF

The following commentary by Sina Jasim, MD, MPH, and Steven A Smith, MD, FACP, was published in the ACP Journal Club section of the April 18 Annals of Internal Medicine. ... The April 18 ACP Journal Club also includes a commentary on ACP's 2017 clinical
May 2017

Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes

with demonstrated cardiovascular benefit, according to an ACP Journal Club commentary. ... The study was published in the Sept. 28, 2017, New England Journal of Medicine and summarized in thewas published in the ACP Journal Club section of the Dec.
January 2018

In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis

The study was published in the October 2016 Diabetes Care. The following commentary by Michael Tanner, MD, FACP, was published in the ACP Journal Club section of the Dec. ... All articles from the January 13, 2017, ACP Diabetes Monthly Newsletter.
January 2017

In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years

of life, according to an ACP Journal Club commentary. ... The following commentary by Lorraine L. Lipscombe, MD, MSc, was published in the ACP Journal Club section of the Aug.
September 2017

In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y

The study was published in the July 28 New England Journal of Medicine and summarized in the July ACP Diabetes Monthly. ... The following commentary by Tejas Patel, MD, MPH, MBA, FACP, was published in the ACP Journal Club section of the Oct.
November 2016

Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk

An ACP Journal Club commentary noted that the mechanism by which liraglutide improves renal outcomes is uncertain and that renal benefit was driven by a decrease in the surrogate outcome of ... The study was published in the Aug. 31, 2017, New England
January 2018

In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y

The study was published in the July 28 New England Journal of Medicine and summarized in the July ACP Diabetes Monthly. ... The following commentary by Michal Mazurek, MD, and Gregory Y.H. Lip, MD, was published in the ACP Journal Club section of the Oct.
November 2016

Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes

Journal Club commentary. ... Egan, MB BCh, PhD, and Victor M. Montori, MD, MSc, FACP, in the ACP Journal Club section of the July 17 Annals of Internal Medicine.
August 2018

Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk

The study was published in the Nov. 10, 2016, New England Journal of Medicine and summarized in the October ACP Diabetes Monthly. ... The following commentary by Anthony A. Donato, MD, MHPE, FACP, was published in the ACP Journal Club section of the Jan.
February 2017

Result Page: Prev   1   2   3   4   5   6   7   8   Next